Trial Profile

Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Stereotactic Body Radiation Therapy and Intermittent Androgen Deprivation Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelitolimod (Primary) ; Pembrolizumab (Primary) ; Abiraterone acetate; Leuprorelin; Prednisone
Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
Focus Adverse reactions; Therapeutic Use

31 May 2025 Status changed from active, no longer recruiting to completed.
06 Dec 2024 Planned End Date changed from 31 Oct 2024 to 31 Aug 2025.
06 Dec 2024 Planned primary completion date changed from 31 Oct 2024 to 31 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com